Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Lexaria Bioscience Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Lexaria Bioscience Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bunka Christopher | Director | 273,543 | Mar 18, 2026 | 1 |
| Christopher Richard | Chief Executive Officer | 65,000 | Jul 30, 2025 | 0 |
| Docherty John Martin | President & CSO | 5,376 | Jul 30, 2025 | 0 |
| McKechnie William Edward | Director | 18,191 | Jul 30, 2025 | 0 |
| Carle Vanessa | Secretary | 750 | Jul 30, 2025 | 0 |
| Reese Albert L Jr | Director | 10,917 | May 16, 2025 | 0 |
| Baxter Nicholas W | Director | – | May 16, 2025 | 0 |
| Bhullar Baljinder | Director | – | May 16, 2025 | 0 |
| Shankman Michael Elliot | Chief Financial Officer | – | May 16, 2025 | 0 |
| Turkel Catherine C. | Director | 3,100 | Aug 13, 2024 | 0 |
| Downey Gregory | Chief Financial Officer | 1,954 | Oct 18, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2025 (view filing) | Jul 29-30 | 1 day | Bunka ChristopherDirector | PPurchase | +27.5K | $0.9157 | +$25.2K | +10.8%281.9K after | 2 lots |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | McKechnie William EdwardDirector | PPurchase | +5.00K | $0.91 | +$4.55K | +37.9%18.2K after | |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Docherty John MartinPresident & CSO | PPurchase | +5.38K | $0.93 | +$5.00K | New position5.38K after | |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Carle VanessaSecretary | PPurchase | +750 | $0.91 | +$682.5 | New position750 after | |
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Christopher RichardChief Executive Officer | PPurchase | +15.0K | $0.91 | +$13.7K | +30.0%65.0K after | |
| Dec 3, 2024 (view filing) | Dec 2-3 | 1 day | Christopher RichardChief Executive Officer | PPurchase | +50.0K | $2.36 | +$118.2K | New position50.0K after | 2 lots |
| Aug 13, 2024 (view filing) | Aug 12 | 1 day | Turkel Catherine C.Director | PPurchase | +1.60K | $3.13 | +$5.01K | +106.7%3.10K after | |
| Aug 1, 2024 (view filing) | Jul 31 | 1 day | Carle VanessaSecretary | SSale | −2.57K | $4.00 | −$10.3K | −100.0%0 after | |
| Feb 27, 2023 (view filing) | Feb 9 | 18 daysLate | Turkel Catherine C.Director | PPurchase | +1.50K | $2.84 | +$4.26K | New position1.50K after | |
| Oct 18, 2022 (view filing) | Oct 14 | 4 days | Downey GregoryChief Financial Officer | PPurchase | +121 | $2.09 | +$252.89 | +6.6%1.95K after | Amended |
| Oct 18, 2022 (view filing) | Oct 12-13 | 6 days | Bunka ChristopherChief Executive Officer | PPurchase | +38.5K | $2.04 | +$78.4K | +17.8%254.4K after | Amended2 lots |